1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Study Progress Updated To ‘Ongoing’: FDA Publishes Interim Report Three Years Into Essure Study

 
• By Hannah Daniel

In a report on Bayer’s postmarket study of Essure, the FDA says Bayer’s study is back on track with its five-year plan.

• Source: Shutterstock

Bayer’s postmarket study of Essure is back on track after a sharp drop in participants in October 2022, the US Food and Drug Administration said in a three-year interim update.

Essure, a sterilization implant marketed by Bayer, was recalled in 2018 in the US. By the end of 2019, all...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Deaths And Serious Injuries Linked To A Pair Of Heart Device Recalls

 
• By Brian Bossetta

Two recent recalls from the US FDA involve three deaths linked to an issue with an Abiomed heart pump — as well as three serious injuries related to angiographic catheters from Cook Medical.

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By Marion Webb

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.

June 2025: A Bumper Month For New EU Medtech Documents And Initiatives

 
• By Amanda Maxwell

The rate at which new documents to support the implementation of EU medtech regulations are issued has slowed of late; but June bucked the trend, with a flurry of activity.